Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 304Stomach Neoplasms 34Neoplasm Metastasis 24Neoplasms 16Colorectal Neoplasms 16Breast Neoplasms, Male 16HER2-positive Breast Cancer 11Inflammatory Breast Neoplasms 10Triple Negative Breast Neoplasms 9Esophageal Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Rectal Neoplasms 7Adenocarcinoma 7Colonic Neoplasms 6Urinary Bladder Neoplasms 5Pathologic Complete Response 5Biliary Tract Neoplasms 5Urologic Neoplasms 4Salivary Gland Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4Recurrence 3Pancreatic Neoplasms 3Neoplastic Cells, Circulating 3Multiple Myeloma 3Meningeal Neoplasms 3HER2-positive Gastric Cancer 3

Interventions

Gemcitabine 20Fluorouracil 14Cisplatin 10Capecitabine 10Leucovorin 8durvalumab 6Oxaliplatin 6Erlotinib Hydrochloride 4Sorafenib 3Radiotherapy 3trifluridine tipiracil drug combination 2trametinib 2regorafenib 2pembrolizumab 2olaparib 2ceralasertib 2Specimen Handling 2Radiosurgery 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Magnetic Resonance Spectroscopy 2Lapatinib 2Irinotecan 2Filgrastim 2AZD 6244 2zimberelimab 1tremelimumab 1titanium silicide 1tislelizumab 1tegafur-gimeracil-oteracil 1seribantumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bile Duct Neoplasms × Trastuzumab × Clear all
NCT00478140 2019-08-20

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
4 enrolled 6 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡